Wednesday, 18 September 2019

CCM Duopharma bags two Excellence Awards in Malaysia

05 July 2018 | News

The two awards CCM Duopharma received include the 2018 Frost & Sullivan Malaysia Pharmaceutical Company of the Year (Generics) and Halal Pharmaceutical Company of the Year

CCM Duopharma Biotech Berhad (CCM Duopharma) has been honored with two awards at the annual Frost & Sullivan Malaysia Excellence Awards banquet, held at the Hilton Kuala Lumpur.

The two awards CCM Duopharma received include the 2018 Frost & Sullivan Malaysia Pharmaceutical Company of the Year (Generics) and Halal Pharmaceutical Company of the Year.

Ms. Rhenu Bhuller, Partner & Senior-Vice President, Transformational Health, Asia Pacific at Frost & Sullivan noted that CCM Duopharma's focus on best practices coupled with a robust growth strategy, is gaining it a strategic advantage in the region, given the potential of the market.

"The ASEAN healthcare market is predicted to be worth $137 billion in 2025 with opportunities for generic and halal pharmaceuticals and biosimilars due to the need for affordable care that meets the evolving needs of payors and consumers. With the disease profile in the region, areas such as oncology, cardiovascular diseases and diabetes will continue to have high unmet needs," she explained.

The company has also focused on differentiating itself by aligning to the needs of the industry and clients.

"With a vision to support healthcare needs not just today but for the future, CCM Duopharma is working to ensure that Malaysians and consumers in ASEAN can have access to quality, affordable as well as consumer-friendly products. The company is leading the way in the region through its product portfolio, R&D pipeline and partnership strategies," noted Ms. Rhenu Bhuller. 

The recipients of the annual Frost & Sullivan Malaysia Excellence Awards were identified based on in-depth research conducted by Frost & Sullivan's analysts.

The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends.

The short-listed companies were evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls